Interpretation and reflection on domestic and foreign latest guidelines for hypertension management

doi:10.3877/cma.j.issn.2095-3216.2021.01.001

Abstract

Abstract:

Hypertension is one of the most common chronic diseases, and is the second most recognized risk factor for chronic kidney disease (CKD). Early diagnosis and effective treatment of hypertension can help prevent or delay the occurrence and development of CKD, and also help reduce the risk of cardiovascular events and all-cause death. From 2017 to 2020, the United States, Europe, China, Japan, and the International Society of Hypertension have successively published the latest guidelines for hypertension management. This article mainly reviewed and interpreted the guidelines on the management of hypertension in patients with CKD.

Key words: Hypertension, Chronic kidney disease, Guideline, Interpretation

Xinru Guo, Guangyan Cai. Interpretation and reflection on domestic and foreign latest guidelines for hypertension management[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2021, 10(01): 1-7.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2021.01.001

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2021/V10/I01/1

Figures/Tables 1

References 38

[1]	Oparil S, Acelajado MC, Bakris GL, et al. Hypertension [J]. Nat Rev Dis Primers, 2018, 4: 18014.
[2]	Wang J, Zhang L, Wang F, et al. 中国高血压发病率、知晓率、治疗率和控制率的全国性调查结果[J]. 中华高血压杂志，2015, 23(3): 298.
[3]	Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives [J]. Lancet, 2013, 382(9888): 260-272.
[4]	Horowitz B, Miskulin D, Zager P. Epidemiology of hypertension in CKD [J]. Adv Chronic Kidney Dis, 2015, 22(2): 88-95.
[5]	Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines [J]. Hypertension, 2018, 71(6): 1269-1324.
[6]	Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension [J]. Eur Heart J, 2018, 39(33): 3021-3104.
[7]	Umemura S, Arima H, Arima S, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019) [J]. Hypertens Res, 2019, 42(9): 1235-1481.
[8]	Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension global hypertension practice guidelines [J]. Hypertension, 2020, 38(6): 982-1004.
[9]	中国高血压防治指南修订委员会，高血压联盟(中国)，中华医学会心血管病学分会，等. 中国高血压防治指南(2018年修订版) [J]. 中国心血管杂志，2019, 24(1): 24-56.
[10]	Kramer HJ, Townsend RR, Griffin K, et al. KDOQI US commentary on the 2017 ACC/AHA hypertension guideline [J]. Am J Kidney Dis, 2019, 73(4): 437-458.
[11]	Zheng Y, Tang L, Zhang W, et al. Applying the new intensive blood pressure categories to a nondialysis chronic kidney disease population: the prevalence, awareness and treatment rates in chronic kidney disease patients with hypertension in China survey [J]. Nephrol Dial Transplant, 2020, 35(1): 155-161.
[12]	Zheng Y, Cai GY, Chen XM, et al. Prevalence, awareness, treatment, and control of hypertension in the non-dialysis chronic kidney disease patients [J]. Chin Med J (Engl), 2013, 126(12): 2276-2280.
[13]	McEvoy JW, Daya N, Rahman F, et al. Association of isolated diastolic hypertension as defined by the 2017 ACC/AHA blood pressure guideline with incident cardiovascular outcomes [J]. JAMA, 2020, 323(4): 329-338.
[14]	Bundy JD, Mills KT, He J. Comparison of the 2017 ACC/AHA hypertension guideline with earlier guidelines on estimated reductions in cardiovascular disease [J]. Curr Hypertens Rep, 2019, 21(10): 76.
[15]	Xie Y, Gao J, Guo R, et al. Stage 1 hypertension defined by the 2017 ACC/AHA guideline predicts future cardiovascular events in elderly Chinese individuals [J]. J Clin Hypertens (Greenwich), 2019, 21(11): 1637-1644.
[16]	Yang WY, Melgarejo JD, Thijs L, et al. Association of office and ambulatory blood pressure with mortality and cardiovascular outcomes [J]. JAMA, 2019, 322(5): 409-420.
[17]	Bangash F, Agarwal R. Masked hypertension and white-coat hypertension in chronic kidney disease: a meta-analysis [J]. Clin J Am Soc Nephrol, 2009, 4(3): 656-664.
[18]	Ku E, Hsu RK, Tuot DS, et al. Magnitude of the difference between clinic and ambulatory blood pressures and risk of adverse outcomes in patients with chronic kidney disease [J]. J Am Heart Assoc, 2019, 8(9): e011013.
[19]	Drawz PE, Alper AB, Anderson AH, et al. Masked hypertension and elevated nighttime blood pressure in CKD: prevalence and association with target organ damage [J]. Clin J Am Soc Nephrol, 2016, 11(4): 642-652.
[20]	Banegas JR, Ruilope LM, de la Sierra A, et al. Relationship between clinic and ambulatory blood pressure measurements and mortality [J]. N Engl J Med, 2018, 378(16): 1509-1520.
[21]	Wang C, Zhang J, Li Y, et al. Masked hypertension, rather than white-coat hypertension, has a prognostic role in patients with non-dialysis chronic kidney disease [J]. Int J Cardiol, 2017, 230: 33-39.
[22]	Rossignol P, Massy ZA, Azizi M, et al. The double challenge of resistant hypertension and chronic kidney disease [J]. Lancet, 2015, 386(10003): 1588-1598.
[23]	Muntner P, Anderson A, Charleston J, et al. Hypertension awareness, treatment, and control in adults with CKD: results from the chronic renal insufficiency cohort (CRIC) study [J]. Am J Kidney Dis, 2010, 55(3): 441-451.
[24]	Liu B, Wang Q, Wang Y, et al. Utilization of antihypertensive drugs among chronic kidney disease patients: results from the Chinese cohort study of chronic kidney disease (C-STRIDE) [J]. J Clin Hypertens (Greenwich), 2020, 22(1): 57-64.
[25]	Bundy JD, Li C, Stuchlik P, et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis [J]. JAMA Cardiol, 2017, 2(7): 775-781.
[26]	Modi GK, Agarwal R. What are optimal blood pressure targets for patients with hypertension and chronic kidney disease? [J]. Curr Cardiol Rep, 2015, 17(11): 101.
[27]	Wright JT, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood pressure control [J]. N Engl J Med, 2015, 373(22): 2103-2116.
[28]	Sim JJ, Shi J, Kovesdy CP, et al. Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population [J]. J Am Coll Cardiol, 2014, 64(6): 588-597.
[29]	Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: a review [J]. JAMA, 2019, 322(13): 1294-1304.
[30]	Minutolo R, De Nicola L, Gallo C, et al. Generalizability of SPRINT-CKD cohort to CKD patients referred to renal clinics [J]. J Nephrol, 2019, 32(3): 429-435.
[31]	Appel LJ, Wright JT, Greene T, et al. Intensive blood-pressure control in hypertensive chronic kidney disease [J]. N Engl J Med, 2010, 363(10): 918-929.
[32]	Upadhyay A, Earley A, Haynes SM, et al. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier [J]. Ann Intern Med, 2011, 154(8): 541-548.
[33]	Agostinis-Sobrinho C, Gómez-Martínez S, Nova E, et al. Lifestyle patterns and endocrine, metabolic, and immunological biomarkers in European adolescents: the HELENA study [J]. Pediatr Diabetes, 2019, 20(1): 23-31.
[34]	Li Y, Schoufour J, Wang DD, et al. Healthy lifestyle and life expectancy free of cancer, cardiovascular disease, and type 2 diabetes: prospective cohort study [J]. BMJ, 2020, 368: 16669.
[35]	Clase CM, Barzilay J, Gao P, et al. Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes [J]. Kidney Int, 2017, 91(3): 683-690.
[36]	Hannedouche T, Roth H, Krummel T, et al. Multiphasic effects of blood pressure on survival in hemodialysis patients [J]. Kidney Int, 2016, 90(3): 674-684.
[37]	Ng SYA, Haynes R, Herrington WG. Haemodialysis, blood pressure and risk: at the limit of non-randomized evidence [J]. Nephrol Dial Transplant, 2020, 35(9): 1465-1468.
[38]	Kasiske BL, Anjum S, Shah R, et al. Hypertension after kidney transplantation [J]. Am J Kidney Dis, 2004, 43(6): 1071-1081.

高血压分级		收缩压(mmHg)		舒张压(mmHg)
2017美国高血压新版指南
	1级高血压	130～139	和(或)	80～89
	2级高血压	≥140	和(或)	≥90
2018欧洲、2018中国、2019日本高血压新版指南
	1级高血压	140～159	和(或)	90～99
	2级高血压	160～179	和(或)	100～110
	3级高血压	≥180	和(或)	≥110
2020国际高血压新版指南
	1级高血压	140～159	和(或)	90～99
	2级高血压	≥160	和(或)	≥100

高血压分级		收缩压(mmHg)		舒张压(mmHg)
2017美国高血压新版指南
	1级高血压	130～139	和(或)	80～89
	2级高血压	≥140	和(或)	≥90
2018欧洲、2018中国、2019日本高血压新版指南
	1级高血压	140～159	和(或)	90～99
	2级高血压	160～179	和(或)	100～110
	3级高血压	≥180	和(或)	≥110
2020国际高血压新版指南
	1级高血压	140～159	和(或)	90～99
	2级高血压	≥160	和(或)	≥100

Please choose a citation manager

Content to export